Kirrhos Pharmaceuticals is focused on developing an orally available, small molecule inhibitor for the treatment of non-alcoholic steatohepatitis.
Year Founded: 2019
Year Partnered: 2019
Category: BioTech/Pharma
Fund: Oklahoma Seed Capital Fund
Press Release: Kirrhos Link
